Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $55.28M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.10pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 11.0¢ | Day High | 11.0¢ | Day Low | 11.0¢ | |||
| Daily Volume | 25002 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 10.0¢ | 484595 | 0 | 10.5¢ | 1234 | |
Directors & Senior Management
| Mr. Adam John Gallagher | Company Secretary |
| Mr. Andrew Kevin-John Smith | CEO, MD & Executive Director |
| Mr. Avee Waislitz | Non-Executive Director |
| Mr. Eddie Smith | Chief Sales Officer |
| Mr. Hugh Walter Robertson | Non-Executive Director |
| Mr. Jason Serafino | Chief Operations & Technology Officer |
| Ms. Jodie Bedoya | Independent Non-Executive Director |
| Mr. Joshua Reid | Executive Director |
| Mr. Michael Doery | Independent Director |
| Mr. Paul Robert Dwyer | Independent Chairman |
| Mr. Piero Gross | Chief Risk Officer |
| Mr. Victor Joseph Peplow | Chief Financial Officer |
| Mr. Warrick Lace | Head of Investor Relations & Media |
Data source: ADVFN
